依布利特转复脑栓塞并心房纤颤的临床研究(3)
 |
| 第1页 |
参见附件(1896KB，3页)。
[4] Varriale P,Sedighi A.Acute management of atrial fibrillation and atrial flutter in the critical care unit:should it be ibutilide? Clin Cardiol,2000,23(4):265 -268.
[5] Gowdw RM,Punukollu G,Khan LA,et al.Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter:impact of race on efficacy and safety.Am JTher,2003,10:259-263.
[6] Volgman AS,Carberry PA,Stambler B,et al.Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.J Am Coll Cardiol,1998,31(6):1414-1419.
[7] Kowey PR,Vanderlugt JT,Luderer JR.Safety and risk/ benefit analysis of ibutilide for acute conversion of atrial fibrillation/ flutter.Am J Cardiol,1996,78(8A): 46-52.
[8] Rogers KC,Wolfe DA.Ibutilide:a classⅢrapidly acting antidysrhythmic for atrial fibrillatin of atrial flutter.J Emergency Med,2001,20(1):67-71.
[9] Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation,executive summary.Circulation,2006;114:700- 752.
您现在查看是摘要介绍页，详见PDF附件(1896KB，3页)。